<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845778</url>
  </required_header>
  <id_info>
    <org_study_id>IN58358</org_study_id>
    <nct_id>NCT02845778</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melatonin is an endogenous hormone. It is able to promote nighttime sleeping and could induce
      sleep at daytime in adult and children with the nonpainful diagnostic procedure. However,
      previous formulation had problems of unstability of product and low oral bioavailability.
      Melatonin niosomes oral gels are formulated in order to overcome the problem of drug
      absorption and stability. This study is a randomized, double-blind, three phase crossover
      design in 15 male volunteers. Melatonin niosomes oral gel will be applied at doses 2.5, 5,
      and 10 mg with 7 days washout for each period. The pharmacokinetics data, sleep induction
      effect, and adverse event will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the pharmacokinetics, sleep induction effect, and adverse event
      after apply melatonin niosomes (MN) oral gel 2.5, 5, and 10 mg per dose in 15 male healthy
      volunteers. The pharmacokinetic parameters include maximum plasma concentration (Cmax), area
      under the curve (AUC), time to peak concentration (Tmax), elimination half-life (t1/2). Sleep
      induction will be determined as sleep onset and duration after use MN oral gels using
      actigraph and behavior observation. A polysomnography using electrode placement derive from
      multiple sleep latency test (MSLT) protocol will be used in some subjects. Adverse event will
      be evaluated by investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration-time profile after 2.5, 5, and 10 mg Melatonin niosomes (MN) oral gel single dose administration</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 120, 180, 240, 300, 360 and 480 min after MN oral gel administration</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep induction effect (sleep onset latency, total sleep time, and wake after sleep onset) after 2.5, 5, and 10 mg MN oral gel single dose administration</measure>
    <time_frame>0-480 min after MN oral gel administration</time_frame>
    <description>Sleep induction effect will be measured by using actigraph, behavior observation (all subjects), and Multiple sleep latency test (5 from 15 subjects).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event after 2.5, 5, and 10 mg MN oral gel single dose administration</measure>
    <time_frame>0-24 h after MN oral gel administration</time_frame>
    <description>nausea, vomiting, headache, irritability and others</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pharmacokinetics of Melatonin</condition>
  <arm_group>
    <arm_group_label>melatonin niosomes oral gel 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply onto oral mucosa as single use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin niosomes oral gel 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply onto oral mucosa as single use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin niosomes oral gel 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply onto oral mucosa as single use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Each sachet contains 0.5 g</description>
    <arm_group_label>melatonin niosomes oral gel 2.5 mg</arm_group_label>
    <arm_group_label>melatonin niosomes oral gel 5 mg</arm_group_label>
    <arm_group_label>melatonin niosomes oral gel 10 mg</arm_group_label>
    <other_name>Melatonin niosomes oral gel 5 mg/g</other_name>
    <other_name>Melatonin niosomes oral gel 10 mg/g</other_name>
    <other_name>Melatonin niosomes oral gel 20 mg/g</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  age 18-30 years

          -  body mass index 18.5-25 kg/m2

          -  general good health and no underlying disease by physical examination and laboratory
             testing (blood urea nitrogen, creatinine, bilirubin, aspartate aminotransferase (AST),
             alanine aminotransferase (ALT), alkaline phosphatase, complete blood count)

          -  provide signed informed consent for study participation

        Exclusion Criteria:

          -  history of allergies to melatonin products

          -  use of any drugs, vitamins, or supplements within 30 days before participation

          -  smoke or alcohol consumption within 1 week before participation

          -  blood or plasma donation within 30 days before participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supawan Laohasiriwong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Supawan Laohasiriwong, MD</last_name>
    <phone>+6643363565</phone>
    <email>supawan125@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chatchanok Nukulkit, à¸ºBSc(Pharm)</last_name>
    <phone>+66850117408</phone>
    <email>chatnuk@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Clinical Research Office</name>
      <address>
        <city>Amphur Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>043-366-568-9</phone>
      <email>info@acro-kku.com</email>
    </contact>
    <investigator>
      <last_name>Supawan Laohasiriwong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>July 24, 2016</last_update_submitted>
  <last_update_submitted_qc>July 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Supawan Laohasiriwong</investigator_full_name>
    <investigator_title>Department of Otorhinolaryngology, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 26, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

